Celltrion, Stock Price +1.22% at This Hour... Institutional Investors Net Sell 186,113 Shares in Last 5 Days

As of 12:30 PM on the 18th, Celltrion is trading at 289,500 KRW, up 1.22% from the previous day. The trading volume is 397,564 shares, which is about 43.86% of the previous day's volume. Celltrion is known as a manufacturer of protein and biopharmaceutical products.

On November 16, Jiha Kim, a researcher at Meritz Securities, stated, "The acquisition of Takeda Pharmaceutical's Asia-Pacific business division was completed in December 2020, and revenue recognition has begun (approximately 200 billion KRW annually). By the first half of 2021, Celltrion plans to supply COVID-19 diagnostic kits jointly developed with BBB worth 210 billion KRW. With steady growth in biosimilar products and increased revenue from new business sectors, 2021 will be a year for Celltrion to emerge as a global pharmaceutical company. Stable performance improvement of Remsima SC in Europe and business diversification are expected to drive external growth in 2021. If the COVID-19 antibody treatment is successful, additional revenue is expected through domestic and international sales." He set Celltrion's target price at 370,000 KRW.

Over the past five days, individual investors have net purchased 36,802 shares of Celltrion, while foreigners and institutions have net purchased 177,280 shares and net sold 186,113 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.